The uptrend is mainly based on the good news (Fundamental Analysis) and the technical Analysis respects the good news of this stock.
Hold before going long - wait the right time to buy, even if we are late on this stock - Target Price of $105 based on Fundamental Analysis:
Shares jumped 20% on Monday after the company revealed positive early results from its experimental vaccine for Covid-19, capping off a 309% rally this year.
Goldman Sachs lifted its price target for Moderna stock to $105 from $63 on Monday after first trials for its coronavirus drug showed "encouraging" results.
Moderna announced Monday that all 45 volunteers in the trial produced antibodies to protect against COVID-19 infection. Shares jumped as much as 39% on the news.
The new price target implies a 25% leap from Moderna's price at 12:25 p.m. ET.
Analyst Salveen Richter raised the vaccine's probability of success to 75% from 70%, and projected phase-two studies will begin this quarter.
Hold before going long - wait the right time to buy, even if we are late on this stock - Target Price of $105 based on Fundamental Analysis:
Shares jumped 20% on Monday after the company revealed positive early results from its experimental vaccine for Covid-19, capping off a 309% rally this year.
Goldman Sachs lifted its price target for Moderna stock to $105 from $63 on Monday after first trials for its coronavirus drug showed "encouraging" results.
Moderna announced Monday that all 45 volunteers in the trial produced antibodies to protect against COVID-19 infection. Shares jumped as much as 39% on the news.
The new price target implies a 25% leap from Moderna's price at 12:25 p.m. ET.
Analyst Salveen Richter raised the vaccine's probability of success to 75% from 70%, and projected phase-two studies will begin this quarter.